Zacks Investment Research upgraded shares of Genmab A/S (OTCMKTS:GNMSF) from a hold rating to a strong-buy rating in a report published on Wednesday. The firm currently has $170.00 price target on the stock.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Other equities analysts also recently issued research reports about the stock. HC Wainwright reiterated a buy rating on shares of Genmab A/S in a report on Monday, October 1st. ValuEngine upgraded shares of Genmab A/S from a sell rating to a hold rating in a report on Thursday, July 19th.

Shares of OTCMKTS:GNMSF opened at $139.79 on Wednesday. Genmab A/S has a twelve month low of $138.60 and a twelve month high of $228.00. The company has a market capitalization of $9.96 billion, a P/E ratio of 51.77 and a beta of 0.16.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Featured Article: Why do company’s buyback their stock?

Get a free copy of the Zacks research report on Genmab A/S (GNMSF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with's FREE daily email newsletter.